Related Experiment Video
Updated: Jul 19, 2026
04:22
Application of Laparoscopic Hepatectomy Combined with Intraoperative Microwave Ablation in Colorectal Cancer Liver Metastasis
Published on: March 3, 2023
Therapy for metastatic colorectal cancer
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. goldberg@med.unc.edu
The Oncologist
|October 13, 2006
Summary
Metastatic colorectal cancer survival now exceeds 20 months with advanced chemotherapy. Combining chemotherapy with targeted therapies shows promise, but optimal sequencing requires further research.
Area of Science:
- Oncology
- Medical Oncology
- Gastrointestinal Oncology
Background:
- First- and second-line combination chemotherapy for metastatic colorectal cancer (mCRC) has improved median overall survival to over 20 months.
- Chemotherapy, especially with oxaliplatin, can enable potentially curative resection of advanced colorectal cancer.
- Targeted therapies, including antibodies against vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), are emerging as beneficial additions.
Purpose of the Study:
- To review current treatment strategies for metastatic colorectal cancer.
- To discuss the role of chemotherapy and targeted therapies in improving patient outcomes.
- To highlight the need for establishing optimal sequencing of combined treatment modalities.
Main Methods:
- Review of existing studies and clinical trial data on mCRC treatment.
- Analysis of survival data for patients receiving various chemotherapy and targeted therapy combinations.
- Evaluation of evidence for the efficacy of anti-VEGF and anti-EGFR antibodies.
Main Results:
- Median overall survival for mCRC patients on first- and second-line chemotherapy can exceed 20 months.
- Chemotherapy regimens including oxaliplatin show potential for curative resection in advanced disease.
- Addition of VEGF and EGFR targeted antibodies demonstrates improved outcomes for advanced and metastatic disease.
Conclusions:
- Current chemotherapy regimens offer significant survival benefits for metastatic colorectal cancer.
- Targeted therapies represent a valuable addition to chemotherapy, enhancing patient prospects.
- Further research is essential to determine the optimal sequencing of chemotherapy and biological agents for mCRC treatment.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.